New oral anticoagulants in patients undergoing atrial flutter radiofrequency catheter ablation: an observational study.
Future Cardiol
; 10(6): 699-705, 2014 Nov.
Article
em En
| MEDLINE
| ID: mdl-25495812
ABSTRACT
AIM:
Atrial flutter (AFL) ablation requires optimal periprocedural anticoagulation in order to minimize thromboembolic events/bleeding risk. This study describes the characteristics of patients receiving new oral anticoagulants before AFL ablation and assesses complications.METHODS:
This multicenter, retrospective study reports ischemic and hemorrhagic predischarge, postprocedural complications.RESULTS:
We evaluated 60 patients (62.3% male; mean age 69.2 ± 9.7 years; CHA2DS2-VASc score 2.44 ± 1.46, HAS-BLED score 1.14 ± 0.7). Twenty-one (35.0%) and 23 patients (38.3%) received twice-daily dabigatran 110 or 150 mg; 16 patients (26.6%) received once-daily rivaroxaban (15 mg [n = 5] or 20 mg [n = 11]). Four cases of postprocedural minor bleeding were reported.CONCLUSION:
This is the first study assessing new oral anticoagulants for periprocedural anticoagulation, specifically in patients undergoing AFL ablation. No major bleeding was reported. Further prospective investigation is warranted.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Flutter Atrial
/
Tiofenos
/
Benzimidazóis
/
Morfolinas
/
Beta-Alanina
/
Ablação por Cateter
/
Anticoagulantes
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article